Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Huya Bioscience and Zhejiang Chinese Medical University Life Science College have signed an agreement to ramp up the global drug development of China's novel Traditional Chinese Medicines (TCM).
Subscribe to our email newsletter
Currently, Huya’s novel anti-arrhythmic compound HBI-3000 is under development in both China and the US.
Huya CTO and COO China Clement Gingras said the alliance with Zhejiang Chinese Medical University Life Science College will further strengthen Huya’s collaborative efforts with the faculty and researchers of the university.
"Together, Huya and Zhejiang Chinese Medical University Life Science College will help advance the progression of TCM to the global markets, benefiting patients worldwide," Gingras said.